HLA-A2 antibody [BB7.2] (PE)
GTX80221
Overview
- SupplierGeneTex
- Product NameHLA-A2 antibody [BB7.2] (PE)
- Delivery Days Customer9
- Antibody SpecificityThis antibody recognizes an epitope at the C-terminus of alpha-2 helix and a turn on one of the underlying beta strands within the human HLA-A2 histocompatibility antigen.
- Application Supplier NoteFACS: 20 microl reagent / 100 microl of whole blood or 106 cells in a suspension. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- Clone IDBB7.2
- FormulationLiquid
- Gene ID3105
- Target nameHLA-A
- Target descriptionmajor histocompatibility complex, class I, A
- Target synonymsHLA class I histocompatibility antigen, A alpha chain; HLA class I histocompatibility antigen, A-1 alpha chain; HLAA; leukocyte antigen class I-A; MHC class I antigen HLA-A heavy chain
- Protein IDP01892
- Protein NameHLA class I histocompatibility antigen, A-2 alpha chain
- Scientific DescriptionHLA-A belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domains, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. Hundreds of HLA-A alleles have been described. [provided by RefSeq, Jul 2008]
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Neoantigens as potential vaccines in hepatocellular carcinoma. Reparaz D et al., 2022 Feb, J Immunother CancerRead more
- Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Bonaventura P et al., 2022 Jan 28, Sci AdvRead more
- Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells. Wu L et al., 2018 May 8, Proc Natl Acad Sci U S ARead more
- Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Chung B et al., 2014 Aug 7, Cell RepRead more
- 2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system. Liu B et al., 2014 Jan, Eur J ImmunolRead more